Evan Rogers

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)

Targeted protein degradation: advances in drug discovery and clinical practice

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants